~~WHAT IS~~ **CLAIM~~ED I~~S**~~:~~

1. ~~A method~~Use of a thaizolide agent in the preparation of a medicament ~~o~~for treating an illness caused by a virus belonging to the *Coronaviridae* family, wherein the medicament is to be~~comprising~~ administer~~ed~~ing to a subject in need thereof ~~an effective amount of a thiazolide agent~~ to produce an effective concentration of tizoxanide in a plasma of the subject, wherein the subject displays one or more symptoms of the illness.

2. The ~~method~~use of claim 1, wherein the one or more symptoms further comprise one or more respiratory symptom selected from the group consisting of cough, sore throat, and nasal congestion.

3. The ~~method~~use of claim 1 or 2, wherein the one or more symptoms further comprise one or more constitutional symptoms selected from the group consisting of fatigue, headache, myalgia, and feverishness.

4. The ~~method~~use of any one of claims 1-3, wherein the oral temperature is no less than 37.3ºC.

5. The ~~method~~use of claim 4, wherein the oral temperature is no less than 37.7ºC.

6. The ~~method~~use of any one of the preceding claims, wherein the virus belonging to the *Coronaviridae* family is the sole cause of the illness.

7. The ~~method~~use of any one of claims 1-6, wherein the virus belongs to the *Alphacoronavirus* genus.

8. The method of any one of claims 1-6, wherein the virus belongs to the *Betacoronavirus* genus.

9. The ~~method~~use of any one of claims 1-6, wherein the virus is selected from the group consisting of NL63 coronavirus, HKU1 coronavirus, 229E coronavirus, and OC43 coronavirus.

10. ~~A method~~Use of a thaizolide agent in the preparation of a medicament ~~o~~for preventing a viral respiratory illness, wherein the medicament comprising an effective amount of the

thiazolide agent is to be administered~~ing~~ to a subject~~,~~ who does not display a symptom of the viral respiratory illness, ~~an effective amount of a thiazolide agent~~ to produce an effective concentration of tizoxanide in a plasma of the subject.

11. The ~~method~~use of claim 10, wherein the viral respiratory illness is caused by a virus belonging to the *Coronaviridae* family.

12. ~~A method~~Use of a thaizolide agent in the preparation of a medicament ~~o~~for treating a mild or moderate illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), ~~comprising~~wherein the medicament is to be administered~~ing~~ to a subject in need ~~thereof an effective amount of a thiazolide agent~~ to produce an effective concentration of tizoxanide in a plasma of the subject.

13. The ~~method~~use of claim 12, wherein ~~said administering~~ the medicament comprising the thiazolide agent reduces progression of the subject from the mild or moderate illness to a severe illness.

14. The ~~method~~use of claim 12 or 13, wherein ~~said administering~~the medicament comprising the thiazolide agent reduces a symptom duration of the mild or moderate illness.

15. The ~~method~~use of any one of claims 12-14, wherein the medicament comprising the thiazolide agent is to be ~~a~~ first ~~event of said~~ administered~~ing is performed~~ within 72 hours of a symptom onset of the mild or moderate illness in the subject.

16. The ~~method~~use of claim 15, wherein the medicament comprising the thiazolide agent is to be first ~~event of said~~ administered~~ing is performed~~ less than 36 hours of the symptom onset of the mild or moderate illness in the subject.

17. The ~~method~~use of any one of the preceding claims, wherein the thiazolide agent comprises tizoxanide or a pharmaceutically acceptable salt thereof.

18. The ~~method~~use of any one of claims 1-16, wherein the thiazolide agent comprises a prodrug of tizoxanide.

19. The ~~method~~use of any one of claims 1-16, wherein the thiazolide agent comprises

RM-5061.

20. The ~~method~~use of any one of claims 1-16, wherein the thiazolide agent comprises nitazoxanide.

21. The ~~method~~use of claim 20, wherein ~~said administering comprises administering a~~the medicament comprises a pharmaceutical composition comprising nitazoxanide.

22. The ~~method~~use of claim 21, wherein the pharmaceutical composition is an extended release pharmaceutical composition.

23. The ~~method~~use of claim 21 or 22, wherein the pharmaceutical composition is administered orally.

24. The ~~method~~use of any one of claims 21-23, wherein a daily dose of nitazoxanide to be administered is about 1200 mg.

25. The ~~method~~use of claim 24, wherein the daily dose is to be administered in two administering events per day.

26. The ~~method~~use of any one of claims 24-25, wherein the pharmaceutical composition comprising nitazoxanide is to be~~said~~ administered~~ing is performed~~ for at least 5 days.

27. The ~~method~~use of any one of claims 1-9 and 12-26, wherein ~~said administering~~the medicament reduces a time from a first administering event for the thiazolide ~~compound~~agent till the subject returns to usual health.

28. The ~~method~~use of any one of claims 1-9 and 12-26, wherein ~~said administering~~the medicament reduces a time from a first administering event for the thiazolide ~~compound~~agent till the subject is able to perform normal activities.